Compare SFM & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFM | CRSP |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.2B |
| IPO Year | 2013 | 2016 |
| Metric | SFM | CRSP |
|---|---|---|
| Price | $68.64 | $49.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 23 |
| Target Price | ★ $93.57 | $85.63 |
| AVG Volume (30 Days) | ★ 2.0M | 1.4M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.60 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $8,806,159,000.00 | $289,590,000.00 |
| Revenue This Year | $7.64 | $1,052.09 |
| Revenue Next Year | $7.66 | $273.88 |
| P/E Ratio | $21.37 | ★ N/A |
| Revenue Growth | 14.08 | ★ 9169.85 |
| 52 Week Low | $61.88 | $44.12 |
| 52 Week High | $109.24 | $68.71 |
| Indicator | SFM | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 53.20 | 41.28 |
| Support Level | $63.62 | $45.61 |
| Resistance Level | $68.78 | $60.71 |
| Average True Range (ATR) | 2.36 | 2.64 |
| MACD | 0.76 | -0.27 |
| Stochastic Oscillator | 95.67 | 17.19 |
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.